


*Journal of
Neural
Transmission*

Supplement 45



U. Bonuccelli and J. M. Rabey (eds.)

**Old and New
Dopamine Agonists
in Parkinson's Disease**



Springer-Verlag *Wien New York*

Contents

Pathophysiology of Parkinson's disease

Manfredi, M., Stocchi, F., Vacca, L.: Differential diagnosis of parkinsonism	1
Martignoni, E., Pacchetti, C., Godi, L., Micieli, G., Nappi, G.: Autonomic disorders in Parkinson's disease	11
De Michele, G., Filla, A., Marconi, R., Volpe, G., D'Alessio, A., Scala, R., Ambrosio, G., Campanella, G.: A genetic study of Parkinson's disease	21
Dubois, B., Pillon, B.: Do cognitive changes of Parkinson's disease result from dopamine depletion?	27
Napolitano, A., Cesura, A. M., Da Prada, M.: The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission	35
Stratta, F., Bonci, A., Calabresi, P., Stefani, A., Pisani, A., Bernardi, G., Mercuri, N. B.: Basic research in substantia nigra and ventral tegmental area: clinical implications	47

Dopamine agonists and dopamine receptors

Melamed, E.: Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?	57
Stefani, A., Pisani, A., Bernardi, G., Bonci, A., Mercuri, N. B., Stratta, F., Calabresi, P.: The modulation of dopamine receptors in rat striatum	61
Bodis-Wollner, I., Antal, A.: On the functional significance of primate retinal dopamine receptors	67
Fenu, S., Carta, A., Morelli, M.: Intranigral injections of glutamate antagonists modulate dopamine D1-mediated turning behavior and striatal c-fos expression	75
Barone, P., Popoli, M., Morelli, M., Cicarelli, G., Campanella, G., Di Chiara, G.: Dopamine mediated responses in 6-hydroxydopamine lesioned rats involve changes of the signal transduction	83
Imperato, A., Obinu, M. C., Gessa, G. L.: Is in vivo striatal acetylcholine output under a tonic inhibitory control by dopamine?	91
Blanchet, P. J., Gomez-Mancilla, B., Bédard, P. J.: DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys	103
Pizzolato, G., Chierichetti, F., Rossato, A., Cagnin, A., Fabbri, M., Dam, M., Ferlin, G., Battistin, L.: Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-DOPA in Parkinson's disease: a [123I]-IBZM SPET study	113
Piccini, P., Turjanski, N., Brooks, D. J.: PET studies of the striatal dopaminergic system in Parkinson's disease (PD)	123

Old and new dopamine agonists

Maggio, R., Barbier, P., Corsini, G. U.: Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response	133
Gancher, S.: Pharmacokinetics of apomorphine in Parkinson's disease	137
Surmann, A., Havemann-Reinecke, U.: Injection of apomorphine – a test to predict individual different dopaminergic sensitivity?	143

Montastruc, J. L., Rascol, O., Senard, J. M., Houin, G., Rascol, A.: Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?	157
Scarzella, L., Delsedime, M., Ferrero, B., Giangrandi, C., Priano, L., Rizzone, M., Bergamasco, B.: Apomorphine SC treatment in parkinsonian patients with long term L-DOPA syndrome during L-DOPA drug holiday	163
de Mari, M., Margari, L., Lamberti, P., Illiceto, G., Ferrari, E.: Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients	171
Traversa, R., Pierantozzi, M., Semprini, R., Loberti, M., Cicardi, M. C., Bassi, A., Stanzone, P.: N30 wave amplitude of Somatosensory Evoked Potentials from median nerve in Parkinson's disease: a pharmacological study	177
Piccoli, F., Riuggeri, R. M.: Dopaminergic agonists in the treatment of Parkinson's disease: a review	187
Sampaio, C., Coelho, T., Castro-Caldas, A., Bastos-Lima, A., Levy, A.: The response of "de novo" Parkinson's disease patients to Bromocriptine in a "low and slow" regimen is predictive for prognosis	197
Pezzoli, G., Canesi, M., Pesenti, A., Mariani, C. B.: Pergolide mesylate in Parkinson's disease treatment	203
Rabey, J. M.: Second generation of dopamine agonists: pros and cons	213
Molho, E. S., Factor, S. A., Weiner, W. J., Sanchez-Ramos, J. R., Singer, C., Shulman, L., Brown, D., Sheldon, C.: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease	225
Brooks, D. J., Turjanski, N., Burn, D. J.: Ropinirole in the symptomatic treatment of Parkinson's disease	231
Bonuccelli, U., D'Antonio, P., D'Avino, C., Piccini, P., Muratorio, A.: Dihydroergocryptine in the treatment of Parkinson's disease	239
Dostert, P., Strolin Benedetti, M., Persiani, S., La Croix, R., Bosc, M., Fiorentini, F., Deffond, D., Vernay, D., Dordain, G.: Lack of pharmacokinetic interaction between the selective dopamine agonist cabergoline and the MAO-B inhibitor selegiline	247
Del Dotto, P., Colzi, A., Pardini, C., Lucetti, C., Dubini, A., Grimaldi, R., Bonuccelli, U.: Cabergoline improves motor disability without modifying L-DOPA plasma levels in fluctuating Parkinson's disease patients	259
<i>Neurodegeneration and neuroprotection</i>	
Federico, A., Battisti, C., Formichi, P., Dotti, M. T.: Plasma levels of vitamin E in Parkinson's disease	267
Gsell, W., Reichert, N., Youdim, M. B. H., Riederer, P.: Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro study	271
Masotto, C., Bisiani, C., Camisasca, C., Fusi, R., Ricciardi, S., Fonzi, N., Perbellini, L., Scàtturin, M., Mariani, C. B., Canesi, M., Pezzoli, G.: Effects of acute n-hexane and 2,5-hexanedione treatment on the striatal dopaminergic system in mice	281
Silani, V., Bernasconi, S., Pizzuti, A., Sampietro, A., Brioschi, A., Buscaglia, M., Scarlato, G.: Molecules with neurotrophic effects on the human developing mesencephalic dopaminergic neurons	287
Favit, A., Sortino, M. A., Aleppo, G., Scapagnini, U., Canonico, P. L.: The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine	297
Coppi, G.: Neuroprotective activity of α -dihydroergocryptine in animal models	307